Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Inhibitors

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,824 result(s) found for: Inhibitors. Displaying page 1 of 92.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2018-004891-36 Sponsor Protocol Number: NN7415-4307 Start Date*: 2019-11-20
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B without inhibitors
    Medical condition: Haemophilia A Haemophilia B
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10018938 Haemophilia A (Factor VIII) LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10018939 Haemophilia B (Factor IX) LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: DK (Trial now transitioned) SE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) SK (Prematurely Ended) DE (Trial now transitioned) BG (Completed) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) PT (Trial now transitioned) HR (Completed) HU (Trial now transitioned) LT (Trial now transitioned) EE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-002278-37 Sponsor Protocol Number: panto001 Start Date*: 2008-08-12
    Sponsor Name:Johann Wolfgang Goethe Universität
    Full Title: Auswirkungen von Pantoprazol auf die myokardiale Kontraktilität bei Patienten mit Herzinsuffizienz - influence of pantoprazole on human myocardial contractility at patients with congestive heart fa...
    Medical condition: Recently literature revealed facts, that show H+/K+ ATPase expression is not limited tot he stomach. H+/K+ ATPase was also found in smooth muscle cells and in other tissues (McCabe, R.D. et al., Am...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000510-30 Sponsor Protocol Number: NN7415-4310 Start Date*: 2017-06-08
    Sponsor Name:Novo Nordisk A/S
    Full Title: A Multi-Centre, Randomised, Open-Label, Controlled Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients with Inhibitors
    Medical condition: Haemophilia A with inhibitors Haemophilia B with inhibitors
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10053751 Hemophilia A with anti factor VIII LLT
    20.0 100000004850 10053752 Hemophilia B with anti factor IX LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) DK (Completed) GB (Completed) GR (Prematurely Ended) ES (Completed) AT (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-004010-19 Sponsor Protocol Number: IMEA064 Start Date*: 2021-10-15
    Sponsor Name:IMEA-Fondation Léon M'Ba
    Full Title: Pharmacokinetics of calcineurin & mTOR inhibitors in HIV-1 infected kidney transplant recipients after switch to BIC/FTC/TAF: a pilot study - KINETIK (KIdNEy Transplant bIKtarvy) IMEA 064
    Medical condition: • HIV-1 infected patients > 18 years • Antiretroviral treatment switch to BIC/FTC/TAF decided in standard care by ID physician • Kidney transplant recipient ≥ 3 months • Receiving calcineurin and/o...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001048-24 Sponsor Protocol Number: NN7769-4514 Start Date*: 2021-05-18
    Sponsor Name:Novo Nordisk A/S
    Full Title: A multinational, open-label, randomised, controlled trial to investigate efficacy and safety of NNC0365-3769 (Mim8) in adults and adolescents with haemophilia A with or without inhibitors.
    Medical condition: Haemophilia A Haemophilia A with inhibitors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10018938 Haemophilia A (Factor VIII) LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10053751 Hemophilia A with anti factor VIII LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) SK (Completed) DK (Completed) DE (Completed) BE (Completed) AT (Completed) LV (Completed) LT (Completed) FR (Completed) NL (Completed) PL (Completed) PT (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002580-85 Sponsor Protocol Number: 3d Start Date*: 2005-08-08
    Sponsor Name:Rigshospitalet
    Full Title: Acute haemodynanic effects of Treatment with ACE inhibitores in patients with severe Aortic Stenosis
    Medical condition: Aortic valve stenosis is a reduction of the aortic valve orifice to a degree where emptying of the left ventricule is compromised. The two major causes for aortic valve stenosis is calcific valve d...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001357-52 Sponsor Protocol Number: EnCovid-hidroxiCLOROQUINA Start Date*: 2020-05-13
    Sponsor Name:IDIVAL
    Full Title: Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in...
    Medical condition: Quimioprophylaxis of SARS-CoV-2 infection with hydroxyloquine (HCQ) in patients diagnosed with an immunomediated inflammatory disease who are following a treatment with biological agents and / or J...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10021982 Inflammatory disorders following infection HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-000504-11 Sponsor Protocol Number: NN7415-4616 Start Date*: 2022-04-05
    Sponsor Name:NOVO NORDISK. S.P.A.
    Full Title: Open-label study investigating efficacy, safety and pharmacokinetics of concizumab prophylaxis in children below 12 years with haemophilia A or B with or without inhibitors
    Medical condition: Haemophilia A with or without inhibitors Haemophilia B with our without inhibitors
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10053752 Hemophilia B with anti factor IX LLT
    20.1 100000004850 10053754 Hemophilia B without inhibitors LLT
    20.0 100000004850 10053753 Hemophilia A without inhibitors LLT
    20.0 100000004850 10053751 Hemophilia A with anti factor VIII LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: IT (Trial now transitioned) NO (Trial now transitioned) GR (Trial now transitioned) SE (Trial now transitioned) LT (Trial now transitioned) EE (Completed) BG (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003324-67 Sponsor Protocol Number: BAY_1093884/19580 Start Date*: 2018-06-22
    Sponsor Name:Bayer AG
    Full Title: Multiple escalating dose study of BAY 1093884 in adults with hemophilia A or B with or without inhibitors
    Medical condition: Hemophilia A or B
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10053751 Hemophilia A with anti factor VIII LLT
    20.0 100000004850 10053753 Hemophilia A without inhibitors LLT
    20.0 100000004850 10053752 Hemophilia B with anti factor IX LLT
    20.1 100000004850 10053754 Hemophilia B without inhibitors LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended) AT (Prematurely Ended) BG (Prematurely Ended) FR (Completed) HU (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002230-41 Sponsor Protocol Number: PPH-LYF02 Start Date*: 2015-06-29
    Sponsor Name:Landspitali University Hospital
    Full Title: Pharmacokinetics of Proton Pump Inhibitors in a random Icelandic Population.
    Medical condition: Gastro Oesophageal Reflux Disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IS (Completed)
    Trial results: View results
    EudraCT Number: 2006-006076-38 Sponsor Protocol Number: RLBUHT3173 Start Date*: 2007-04-26
    Sponsor Name:University of Liverpool [...]
    1. University of Liverpool
    2. Royal Liverpool & Broadgreen University Hospitals Trust
    Full Title: The Liverpool HIV TDM Registry: Studying influences upon plasma HIV drug exposure
    Medical condition: Pharmacogenetic study of HIV+ patients receiving antiretroviral therapy. We wish to correlate drug concentration with host genetic patients receiving certain HIV drugs. No dosage modification wil...
    Disease:
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-003425-81 Sponsor Protocol Number: RLBUHT2763 Start Date*: 2007-03-29
    Sponsor Name:University of Liverpool
    Full Title: Host genetic factors influencing drug disposition and response to HIV treatment
    Medical condition: Pharmacogeneric study of HIV+ patients receiving antiretroviral therapy. We wish to correlate drug concentration with host genetic patients receiving certain HIV drugs. No dosage modification will...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-004889-34 Sponsor Protocol Number: NN7415-4311 Start Date*: 2019-10-07
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B with inhibitors
    Medical condition: Haemophilia A with inhibitors Haemophilia B with inhibitors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10053751 Hemophilia A with anti factor VIII LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10053752 Hemophilia B with anti factor IX LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: DK (Trial now transitioned) SE (Trial now transitioned) AT (Completed) FR (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) SK (Completed) NO (Completed) BG (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) HR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-002627-90 Sponsor Protocol Number: 3589 Start Date*: 2008-09-05
    Sponsor Name:Royal Liverpool and Broadgreen University Hospitals NHS Trust [...]
    1. Royal Liverpool and Broadgreen University Hospitals NHS Trust
    2. University of Liverpool
    Full Title: Intracellular boosting of HIV protease inhibitors through inhibition of transport - a novel strategy for potentiating HIV therapy
    Medical condition: This study is to evaluate the intracellular boosting effect of furosemide and dipyridamole of the HIV protease inhibitors in HIV positive patients.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002641-37 Sponsor Protocol Number: NN7415-4580 Start Date*: Information not available in EudraCT
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of once-weekly subcutaneous administration of concizumab prophylaxis in patients with haemophilia A and B, with or without inhibitors
    Medical condition: Haemophilia A Haemophilia A with inhibitors Haemophilia B Haemophilia B with inhibitors
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10018938 Haemophilia A (Factor VIII) LLT
    20.0 100000004850 10053751 Hemophilia A with anti factor VIII LLT
    20.0 100000004850 10018939 Haemophilia B (Factor IX) LLT
    20.0 100000004850 10053752 Hemophilia B with anti factor IX LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: SE (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005916-23 Sponsor Protocol Number: ML39791 Start Date*: 2020-12-18
    Sponsor Name:Genentech, Inc.
    Full Title: A Phase IV, Multicenter, Single-Arm, Open-Label Study of Emicizumab Prophylaxis in Patients With Hemophilia A With or Without Inhibitors Undergoing Minor Surgical Procedures
    Medical condition: Hemophilia A with or without inhibitors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10053753 Hemophilia A without inhibitors LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10053751 Hemophilia A with anti factor VIII LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-003256-32 Sponsor Protocol Number: MO42245 Start Date*: 2021-04-14
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: AN INTERVENTIONAL OPEN-LABEL MULTICENTER PHASE IV STUDY TO EVALUATE THE IMPACT OF EMICIZUMAB ON HEALTH-RELATED QUALITY OF LIFE, PHYSICAL ACTIVITY, AND JOINT HEALTH IN PATIENTS WITH SEVERE HEMOPHILI...
    Medical condition: Severe hemophilia A without factor VIII inhibitors
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10053753 Hemophilia A without inhibitors LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: SE (Completed) NO (Completed) FI (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-004538-14 Sponsor Protocol Number: TACTOR-2013 Start Date*: 2014-07-30
    Sponsor Name:Azienda Ospedaliera Universitaria Integrata Verona
    Full Title: Identification of a specific systemic transcriptome able to differentiate patients with renal transplantation in chronic treatment with tacrolimus from those with mTOR inhibitors.
    Medical condition: Renal Transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003970-41 Sponsor Protocol Number: CRU3 Start Date*: 2017-07-06
    Sponsor Name:UNIVERSITÀ DEGLI STUDI MILANO BICOCCA
    Full Title: A PHASE 2 OPEN LABEL STUDY OF ORAL LORLATINIB (PF-06463922) IN PATIENTS WITH RELAPSED ALK POSITIVE LYMPHOMA PREVIOUSLY TREATED WITH ALK INHIBITORS
    Medical condition: Anaplastic Large Cells Lymphoma (ALCL) ALK+
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073478 Anaplastic large-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003467-26 Sponsor Protocol Number: NN7769-4516 Start Date*: 2021-11-30
    Sponsor Name:Novo Nordisk A/S
    Full Title: Safety, efficacy and exposure of subcutaneously administered NNC0365-3769 (Mim8) prophylaxis in children with haemophilia A with or without FVIII inhibitors
    Medical condition: Haemophilia A Haemophilia A with inhibitors
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10018938 Haemophilia A (Factor VIII) LLT
    20.0 100000004850 10053751 Hemophilia A with anti factor VIII LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) PL (Completed) IT (Completed) ES (Ongoing) PT (Completed) LT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 09:16:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA